DTU
DTU

Early Diabetes Intervention Trial

Principal investigator:Rury Holman

Sponsors:Bayer plc
Merck-Lipha (UK)

Funder:Bayer
Merck-Lipha

Reference number:ISRCTN96631607

The Early Diabetes Intervention Trial (EDIT) was a six-year, prospective, randomised, double-blind, placebo-controlled study in subjects thought to be at increased risk of developing diabetes, and who had two consecutive fasting plasma glucose levels in the range 5.5 to 7.7 mmol/L. The primary aim of the trial was to determine whether deterioration in glycaemic tolerance towards diabetes could be delayed or prevented using an alpha-glucosidase inhibitor (acarbose) or a biguanide (metformin).

Results

The trial results were presented at the 2003 Diabetes UK meeting.

News

Prevalence of Glucokinase (GCK) Mutations in Individuals Screened for Fasting Hyperglycaemia

09-Jan-2009
News Image

[Link]

Prevalence of GCK mutations in fasting hyperglycaemia

14-Nov-2008
News Image

[Link]


[News archive]